Search

Displaying results 1621 - 1630 of 5897 in total
  1. Drug

    Methyclothiazide

    go.drugbank.com/drugs/DB00232
    ApprovedWithdrawn

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

  2. Drug

    Azelaic acid

    go.drugbank.com/drugs/DB00548
    ApprovedInvestigational

    Azelaic acid's antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis. … Azelaic acid is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%.

    Products: Zeliris Cream 20% w/w
  3. Drug

    Cinnamyl alcohol

    go.drugbank.com/drugs/DB14186
    Approved

    Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% [A34266]. Sensitivity to cinnamyl alcohol may be identified with a clinical patch test. … Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as [DB14184] within commercial products.

  4. Drug

    Atractylodes lancea root oil

    go.drugbank.com/drugs/DB14338
    Approved

    Atractylodes lancea root oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: O Hui White Extreme Blemish Balm, OHUI White Extreme Illuminating Pact No.10
  5. Drug

    Tolevamer

    go.drugbank.com/drugs/DB01344
    Approved

    Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels.

  6. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.

  7. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

  8. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    Compared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery … release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.

  9. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    [A264389] Vonicog alfa works to reduce bleeding events and bleeding times in patients with vWD, who have deficiencies in VWF.[A264389] … [A264444] Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,[L51274] which is a critical plasma glycoprotein involved in platelet adhesion and aggregation.

  10. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for … progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.